Liver Institute Northwest | Seattle, WA

Research site

(Unclaimed)

Location

3216 NE 45th Place, Suite 212, Seattle, Washington, United States of America

Site insights

Top conditions

Top treatments

Cilofexor

Resmetirom

Ursodeoxycholic Acid

Elafibranor

Obeticholic Acid

UDCA

MGL-3196

Volixibat

Pemafibrate

DA-1241

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 33 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling

NASH

Cirrhosis, Liver

Drug: Resmetirom

Drug: Placebo

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Procedure: Liver Biopsy

Drug: MGL-3196

A Study of BOS-580 in Obese Subjects At Risk For, or with Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) with an Extension

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic ste...

Active, not recruiting

Nonalcoholic Steatohepatitis (NASH)

Drug: Placebo

Drug: Efimosfermin

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Active, not recruiting

Primary Sclerosing Cholangitis

Drug: Placebo Matched to Elafibranor 80 mg

Drug: Placebo Matched to Elafibranor 120 mg

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

Begins enrollment in 2 months

Primary Sclerosing Cholangitis (PSC)

Drug: Placebo

Drug: LB-P8 low-dose

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

PBC

Primary Biliary Cholangitis

Drug: Volixibat

Drug: Placebo

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

Primary Sclerosing Cholangitis

Drug: Placebo

Drug: Volixibat

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo (NNC0194-0499)

Drug: NNC0174 0833 placebo

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling

Primary Biliary Cirrhosis

Drug: Seladelpar 10 mg Capsule

Drug: Seladelpar 5 mg Capsule

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis (AFFIRM)

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Enrolling

Primary Biliary Cholangitis

Drug: Seladelpar

Drug: Placebo

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting

Primary Biliary Cirrhosis

Drug: Placebo

Drug: Elafibranor 80mg

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: Cilofexor (CILO)/Firsocostat (FIR)

Drug: PTM SEMA

Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: HM15211

Drug: Placebo of HM15211

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

Enrolling

Primary Biliary Cholangitis

Drug: K-808 (Dose A)

Drug: Placebo

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Enrolling

NASH

Drug: K-877-ER

Drug: Placebo